Retraction notice to 'The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC' [EBioMedicine 37 (2018) 188-204].
作者信息
Jin Dan, Guo Jiwei, Wang Deqiang, Wu Yan, Wang Xiaohong, Gao Yong, Shao Cuijie, Xu Xin, Tan Shuying
机构信息
Department of Pain, Binzhou Medical University Hospital, Binzhou 256603, PR China.
Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China.
出版信息
EBioMedicine. 2021 Jan;63:103169. doi: 10.1016/j.ebiom.2020.103169.
Abstract
摘要
相似文献
1
Retraction notice to 'The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC' [EBioMedicine 37 (2018) 188-204].撤回声明：“抗肿瘤药物二甲双胍通过干扰IRF-1与非小细胞肺癌中YAP启动子的结合来下调YAP”[《电子生物医学》37卷（2018年）第188 - 204页]
EBioMedicine. 2021 Jan;63:103169. doi: 10.1016/j.ebiom.2020.103169.
2
The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.抗肿瘤药物二甲双胍通过干扰 IRF-1 与 NSCLC 中 YAP 启动子的结合来下调 YAP。
EBioMedicine. 2018 Nov;37:188-204. doi: 10.1016/j.ebiom.2018.10.044. Epub 2018 Oct 30.
3
Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.从不吸烟的非小细胞肺癌作为一个独立实体：临床病理特征与生存情况
Cancer. 2008 Sep 1;113(5):1012-8. doi: 10.1002/cncr.23679.
4
Retraction notice to "Corrigendum to 'MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway' [EBioMedicine 46 (2019) 66-78]" [EBioMedicine 55 (2020) 102772].撤回声明：“《对〈MicroRNA-134通过PLXNA1介导的MAPK信号通路预防食管鳞状细胞癌进展〉的勘误》[《E生物医学》46 (2019) 66 - 78]”[《E生物医学》55 (2020) 102772]
EBioMedicine. 2024 May;103:105106. doi: 10.1016/j.ebiom.2024.105106. Epub 2024 Apr 4.
5
Retraction notice to "Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter" [EBioMedicine 55 (2020) 102694].撤回声明：“长链非编码RNA CDKN2B-AS1通过在CDKN2B启动子中形成RNA-DNA三链体促进动脉粥样硬化斑块形成”[《转化医学杂志》55卷（2020年），第102694页] 。
EBioMedicine. 2024 Jun;104:105193. doi: 10.1016/j.ebiom.2024.105193. Epub 2024 Jun 3.
6
Retraction notice to 'The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells' [EBioMedicine 35 (2018) 204-221].撤回通知：“miR 495 - UBE2C - ABCG2/ERCC1轴通过下调顺铂耐药非小细胞肺癌细胞中的耐药基因逆转顺铂耐药性”[《电子生物医学》35 (2018) 204 - 221]
EBioMedicine. 2021 Jan;63:103168. doi: 10.1016/j.ebiom.2020.103168.
7
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.抑制ERK1/2可下调人非小细胞肺癌细胞中的Hippo/YAP信号通路。
Oncotarget. 2015 Feb 28;6(6):4357-68. doi: 10.18632/oncotarget.2974.
8
Retraction notice to " HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells" [eBioMedicine 48 (2019) 117 - 129].撤回声明：“HBV编码的miR-2通过下调TRIM35但上调RAN在肝癌细胞中发挥癌基因作用”[《电子生物医学》48卷（2019年）第117 - 129页]
EBioMedicine. 2021 Oct;72:103667. doi: 10.1016/j.ebiom.2021.103667.
9
Hippo/YAP pathway for targeted therapy.Hippo/YAP 通路的靶向治疗。
Transl Lung Cancer Res. 2014 Apr;3(2):75-83. doi: 10.3978/j.issn.2218-6751.2014.02.03.
10
Retraction notice to "LSAMP-AS1 binds to microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN" [eBioMedicine 50 (2019) 178 - 190].撤回通知：“LSAMP-AS1通过上调肿瘤抑制因子DCN与微小RNA-183-5p结合以抑制前列腺癌进展”[《电子生物医学》50 (2019) 178 - 190]
EBioMedicine. 2021 Oct;72:103665. doi: 10.1016/j.ebiom.2021.103665.
本文引用的文献
1
The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.抗肿瘤药物二甲双胍通过干扰 IRF-1 与 NSCLC 中 YAP 启动子的结合来下调 YAP。
EBioMedicine. 2018 Nov;37:188-204. doi: 10.1016/j.ebiom.2018.10.044. Epub 2018 Oct 30.
Zotero 插件